Etanercept dosing in the effectiveness cohort
| Dosing characteristic | Effectiveness cohort N=43 |
| Restricted to patients weighing < 62.5 kg at etanercept initiation | |
| Weekly etanercept dose at initiation, median (Q1, Q3), mg/kg (number of patients with available data) | 0.8 (0.8, 0.9) (37) |
| Restricted to patients weighing ≥ 62.5 kg at etanercept initiation, n (%) (number of patients with available data) | |
| Received 50 mg weekly | 5 (83.3) (6) |
| Received > 50 mg weekly | 0 (0) (6) |
| Received <50 mg weekly | 1 (16.7) (6) |
N=number of patients who met the criteria for the effectiveness cohort, that is, initiated etanercept after CARRA Registry enrolment, had a registry visit ±14 days from etanercept initiation had uninterrupted etanercept use, and had a 6-month or 12-month follow-up visit. Dosing calculation reflects the weight at visit closest to the time of etanercept initiation (within 9 months before 9 months post-initiation); no patients were excluded due to no weight available for dose calculation.
CARRA, Childhood Arthritis and Rheumatology Research Alliance; Q1, quartile 1; Q3, quartile 3.